STOCK TITAN
  1. Home
  2. News
  3. ICPT

Intercept Pharmaceuticals Inc - ICPT STOCK NEWS

Welcome to our dedicated news page for Intercept Pharmaceuticals (Ticker: ICPT), a resource for investors and traders seeking the latest updates and insights on Intercept Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intercept Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intercept Pharmaceuticals's position in the market.

News
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Rhea-AI Summary
Intercept Pharmaceuticals announces FDA acceptance of sNDA for Ocaliva in treating primary biliary cholangitis, with a PDUFA target action date of October 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
Rhea-AI Summary
Intercept Pharmaceuticals, Inc. (ICPT) - New data from Phase 2 studies show combination of OCA + bezafibrate achieved biochemical remission in 40-44% of PBC patients in the first 12 weeks. Results support progression to Phase 3 trials of sustained release formulation of bezafibrate with low doses of OCA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
Rhea-AI Summary
Intercept Pharmaceuticals, Inc. (ICPT) announces new data from a sub-analysis of the Phase 3 POISE trial evaluating the impact of obeticholic acid (OCA) on primary biliary cholangitis (PBC). The analysis suggests OCA’s potential to reduce GGT and ALP levels below thresholds that predict improved outcomes, to be presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Boston on November 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Rhea-AI Summary
Alfasigma (ALFA) and Intercept Pharmaceuticals (ICPT) announced the completion of Alfasigma's acquisition of Intercept. The deal adds Ocaliva, an FDA-approved treatment for primary biliary cholangitis, to Alfasigma's portfolio, strengthening its presence in the US market. The acquisition also enhances Alfasigma's innovation and R&D pipeline, with the addition of a novel fixed-dose combination for PBC treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Rhea-AI Summary
Alfasigma (NASDAQ: ICPT) has completed the tender offer to purchase all outstanding shares of Intercept Pharmaceuticals, Inc. at a price of USD 19.00 per share. 31,158,412 shares, representing approximately 74.5% of Intercept’s outstanding shares, were tendered and not withdrawn. Alfasigma expects to complete the acquisition on November 8, 2023, through a merger without a vote or meeting of Intercept’s stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc.
Rhea-AI Summary
Alfasigma's proposed acquisition of Intercept Pharmaceuticals has passed the waiting period under the HSR Act. Other conditions still need to be satisfied for the tender offer to be completed. The offer and withdrawal rights will expire on November 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
acquisition
News
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
Rhea-AI Summary
Persephone Biosciences appoints Daniel Bradbury as Chair of the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences
Rhea-AI Summary
Alfasigma announces cash tender offer to purchase Intercept Pharmaceuticals shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Rhea-AI Summary
Alfasigma to acquire Intercept for $19.00 per share in cash, representing an 82% premium to Intercept's closing price on September 25, 2023. The acquisition will expand Alfasigma's portfolio in gastroenterology and hepatology and strengthen its presence in the U.S. market. Alfasigma adds Ocaliva®, generating $152 million in revenue in 1H 2023. Transaction expected to close by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
79.21%
Tags
acquisition
News
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
Rhea-AI Summary
Intercept Pharmaceuticals to participate in fireside chats and investor meetings at upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.84%
Tags
conferences
Stock ICPT logo
Intercept Pharmaceuticals Inc

Nasdaq:ICPT

ICPT Rankings

N/A Ranked by Market Cap
#562 Ranked by Stock Gains
N/A Ranked by Dividends

ICPT Stock Data

794.69M
34.49M
3.13%
81.3%
24.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Morristown

About ICPT

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.